Paul Saladino· MD
look at the mortality benefits here ideal trial 0 2% cards Ator 1.5 Aspen Ator zero Jupiter 0.55% improve it .1%
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
look at the mortality benefits here ideal trial 0 2% cards Ator 1.5 Aspen Ator zero Jupiter 0.55% improve it .1%
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
after 2004 Statin trials do not look nearly as impressive and the problem with this is that when you look at Saturn efficacy in reducing cardiovascular disease or overall mortality those are very important endpoints to consider and they're different endpoints
when you lowered LDL in some of these trials like the Seas trial like enhance which was looking at intimal medial thickness getting worse this is just CHF which was all cause death as the outcome which got worse when you lowered LDL